Dose escalation study of ⁸⁹Zr-GSK2849330 in CHL-1 xenograft tumor bearing mice as measured ex-vivo using a Gamma Counter at 72 hours.

<p>Each group received a tracer dose (~0.14 mg/kg) of ⁸⁹Zr-GSK2849330 plus a dose of non-labeled GSK2849330 (0, 0.3, 1, 3, or 10 mg/kg) (panels A and B). The normalized liver uptake to blood uptake ratio (Panel C) showed a significant decrease with the increased non labeled GSK2849330 (***p<0.01 vs 0 mg/kg; ^##p<0.01, ^###p<0.001 vs 0.3 mg/kg using One-way ANOVA). The normalized tumor uptake to blood uptake ratio (Panel D) showed a significant decrease with the increased non labeled GSK2849330 from 0.3 and 1 mg/kg compared to the 10 mg/kg group (^#p<0.05 vs 1 mg/kg; ** p<0.01, *** p<0.001 vs 10 mg/kg using One-way ANOVA). Data is presented as mean±SEM (<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0176075#pone.0176075.s002" target="_blank">S2 Table</a>).